A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
Clinical trial NCT07294534 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07294534
- Sponsor
- Shanghai Henlius Biotech
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-27
- Primary completion
- 2028-09-30
- Enrollment
- 817
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.